Formycon — H118 results: FYB201 registration closer

Formycon (DB: FYB)

Last close As at 19/04/2024

61.30

−0.20 (−0.33%)

Market capitalisation

677m

More on this equity

Research: Healthcare

Formycon — H118 results: FYB201 registration closer

Formycon has reported record H118 revenues, boosted by the one-off transfer of FYB202 into a joint venture with Aristo Pharma and payments stemming from the out-licensed assets FYB201 and FYB203. We believe that Formycon biosimilars FYB201 (Lucentis) and FYB203 (Eylea) are set to enter neovascular age-related macular degeneration (nAMD) market post-2020. Cash and equivalents at end-H118 were €11.8m and should give a cash runaway until 2020 based on H118 cash burn. Formycon guides for FY18 revenues of €35m.

Analyst avatar placeholder

Written by

Healthcare

Formycon

H118 results: FYB201 registration closer

Pharma & biotech

Scale research report - Update

27 September 2018

Price

€32.05

Market cap

€301m

Share price graph

Share details

Code

FYB

Listing

Deutsche Börse Scale

Shares in issue

9.4

Cash and cash equivalents
at end-June 2018

€11.8m

Business description

Formycon is a biotechnology company focused on biosimilars. The lead product is FYB201, a Lucentis biosimilar that has completed Phase III; FYB203 is an Eylea biosimilar in the preclinical stage. They are both out-licensed. FYB202, a biosimilar candidate of Stelara, is being developed in a joint venture with Aristo Pharma. Formycon also has an undisclosed biosimilar, FYB205.

Bull

Leading biosimilars company addressing an $11–12bn market.

Two partnered products in multi-million-euro deals.

Potential first-to-market advantage for FYB201.

Bear

No EMA guidance for intraocular biosimilars.

US biosimilar market still immature.

Lucentis sale declined since 2014.

Analysts

Dr Sean Conroy

+44 (0)20 3077 5700

Juan Pedro Serrate

+44 (0)20 3077 5700

Formycon has reported record H118 revenues, boosted by the one-off transfer of FYB202 into a joint venture with Aristo Pharma and payments stemming from the out-licensed assets FYB201 and FYB203. We believe that Formycon biosimilars FYB201 (Lucentis) and FYB203 (Eylea) are set to enter neovascular age-related macular degeneration (nAMD) market post-2020. Cash and equivalents at end-H118 were €11.8m and should give a cash runaway until 2020 based on H118 cash burn. Formycon guides for FY18 revenues of €35m.

FYB201 on track to lead Lucentis biosimilars

In May 2018, Formycon announced that the primary endpoint in the COLUMBUS-AMD Phase III study of FYB201 had been met. The last patient completed treatment in June 2018; Formycon expects to release further information in H218. Partner Bioeq IP (which holds exclusive global rights to FYB201 in a €100m+ deal) will use these data for regulatory filings in the US and EU, and aims to launch the product in 2020 (US) and 2022 (EU) on patent expiration(s). Global Lucentis sales increased in H118 to $1.9bn (H117: $1.7bn), but have fallen since H114 ($2.1bn), reflected in part by the increased use of Eylea and continued off-label use of Avastin in nAMD. We believe this may introduce some uncertainly into the sales of Lucentis, but think the case for a low-cost alternative in the form of a biosimilar of the branded Lucentis remains strong.

Moving further along in nAMD and beyond

Formycon’s Eylea biosimilar FYB203 (out-licensed to Santo Holding) is in advanced preclinical studies with the aim of entering clinical trials for nAMD (timeline not provided). Total development, regulatory and commercial milestones could be over three-digit million euros. Global sales of Eylea were $3.3bn in H118 (H117: $2.8bn). Eylea patents expire in 2023 (US) and 2025 (EU). With other innovative treatments set to enter the nAMD market over the coming years, developing (and out-licensing) assets outside nAMD will be key to mitigating their risk and diversifying future revenue streams. The execution of the FYB202 (Stelara biosimilar) deal with Aristo Pharma is evidence of this; we think that near-term updates on FYB202 and, in the longer term, on FYB205 (undisclosed biosimilar), are important for growth.

Valuation: Share price flat year to date

Formycon’s market cap is c €301m and its EV is c €289.2m. Progression of assets in nAMD and additional indications will be key drivers for adding value.

Consensus estimates

Year
end

Revenue
(€m)

PBT

(€m)

EPS

(€)

DPS
(€)

P/E

(x)

Yield
(%)

12/16

19.53

(4.06)

(0.46)

0.0

N/A

N/A

12/17

29.43

(1.58)

(0.17)

0.0

N/A

N/A

12/18e

33.60

2.70

0.29

0.0

N/A

N/A

12/19e

27.10

(3.00)

(0.32)

0.0

N/A

N/A

Source: Bloomberg consensus estimates, Formycon data

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

Financials: H118 results review

Formycon reported revenues of €25.4m in H118 (vs €8.1m in H117). This was primarily driven by inward cash flow from the compensation for development work received for out-licensed projects. This was further boosted by rebooking and the transfer of IP associated with FYB202 into the joint venture with Aristo Pharma (€8.5m non-cash). The company guides for FY18 revenue of €35m.

Total operating expenses increased to €17.3m in H118 from €11.0m in H117, mostly due to increased third-party services, which relate to the clinical and preclinical development of its products. Net income was €7.6m vs a loss of €2.9m in H117. Formycon generated €12.9m cash from operations, vs c €0.8m in H117, resulting in cash and equivalents of €11.8m at end-H117. Formycon has no financial debt.

Exhibit 1: Financial summary

Year-end 31 December (€m)

2014

2015

2016

2017

H118

Income statement

Revenue

12.70

16.92

19.53

29.43

25.41

Profit before tax (as reported)

0.87

0.60

(4.06)

(1.58)

8.21

Net income (as reported)

0.87

0.60

(4.07)

(1.58)

7.59

EPS (as reported)* (€)

0.10

0.06

(0.46)

(0.17)

0.83

Dividend per share (€)

0.00

0.00

0.00

0.00

0.00

Balance sheet

Total non-current assets

4.03

3.74

4.40

4.11

20.27

Total current assets

12.88

23.41

20.80

26.72

21.83

Total assets

16.91

27.15

25.19

30.83

42.20

Total current liabilities

(3.26)

(1.61)

(3.58)

(4.01)

(6.56)

Total non-current liabilities

(0.53)

(0.66)

(0.72)

(1.27)

(2.51)

Total liabilities

(3.80)

(2.28)

(4.30)

(5.28)

(9.07)

Net assets

13.11

24.87

20.89

25.54

33.13

Shareholders’ equity

13.11

24.87

20.89

25.54

33.13

Cash flow statement

Net cash from operating activities

(0.03)

0.52

(5.04)

(4.20)

12.92

Net cash from investing activities

(0.57)

(0.60)

(1.35)

(0.51)

(16.56)

Net cash from financing activities

(0.01)

11.15

0.06

6.20

(0.02)

Net cash flow

(0.61)

11.07

(6.33)

1.51

(3.66)

Cash & cash equivalent end of year

0.29

20.30

13.97

15.48

11.82

Source: Formycon accounts, *Bloomberg

Valuation

Formycon’s market cap is c €292.4m and EV is c €280.6m; the share price has remained flat year-to-date despite positive news on the development of FYB201. We believe that Formycon’s product candidates are well positioned to capture a significant portion of the biologics nAMD market, which is forecast to reach c $10bn in 2020, according to Evaluate Pharma. However, there is a degree of uncertainty surrounding how much of the market assets FYB201 (Lucentis biosimilar) and FYB203 (Eylea biosimilar) can capture (and, by extension, revenue from royalties).

For example, positive Phase III readouts for Novartis’s anti-VEGF single chain antibody fragment (RTH258) and a planned regulatory filling during H218 could see the top-line treatment for nAMD move beyond Eylea before commercialisation of FYB203 is realised (post patent expiries in 2023).In conjunction to this, a recent (September 2018) landmark ruling by UK courts (which deemed off-label use of Avastin lawful) could see sales of Lucentis continue to decline, introducing further uncertainty into the peak sales that FYB201 could capture. This being said, both Eylea and Lucentis are well established in the clinic and are still likely to maintain multi-billion dollar sales until their patents expire. Favourably priced biosimilars (ie FYB201 and FYB203), which can demonstrate safety and efficacy in-line with these treatments, are likely to capture a significant portion of their sales and may even provide economical alternatives to dissuade the off-label use of Avastin, which is not licensed for the treatment of nAMD.

Achieving first-to-market status for out-licensed assets FYB201 and FYB203 will be important for maximising revenues if they reach commercialisation (post clinical and regulatory hurdles). We see competition in the Lucentis biosimilar market primarily from Samsung Bioepis’s SB11 (currently in Phase III); Xbrane’s Xlucane and Coherus’s CHS-3351, which are in the early stages of development. We continue to believe that Formycon has a potential first-to-market advantage for a biosimilar of Lucentis in regulated markets. For FYB203 (Eylea), competition comes primarily from Mylan’s and Momenta Pharmaceuticals’ M710, which is ready to start pivotal clinical trials. Alteogen’s ALT-L9 and Coherus’s CHS-2020 are in early stages of development and it is not clear whether they intend to enter the same regulated markets as Formycon.

Outside nAMD, we believe that near-term updates on FYB202 and, in the longer term, on FYB205 will provide further upside.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Any Information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors.

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Formycon

View All

Latest from the Healthcare sector

View All Healthcare content

Research: TMT

Keywords Studios — Strengthening position in an attractive market

Keywords has built an enviable position of strength, servicing a global games market expected to sustain 10% growth. Pockets of volatility, possibly related to the dramatic success of Fortnite create some near-term uncertainty, but we believe company’s strength of model and customer diversity will continue to enable the group to outgrow the games market in the medium to long term. At 36x FY19e earnings, strong growth is priced in, but continued execution should drive positive shareholder returns.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free